Sell Your Medical Device Manufacturing Business in 2026: 8-12x EBITDA, ISO 13485, FDA-Registered Premium

Medical device manufacturing is the highest-multiple sub-vertical in U.S. industrial M&A in 2026. ISO 13485-certified, FDA 21 CFR 820 compliant manufacturers with 510(k) cleared product families trade at 8-12x EBITDA standard, with platform-quality assets (proprietary IP, recurring consumables / disposables revenue, CDMO platforms with diversified customer bases) clearing 12-15x. The reason is structural: medical device qualification is a 5-10 year build-out moat — ISO 13485 certification, FDA registration, 510(k) clearance, MDSAP / EU MDR compliance, validated cleanroom infrastructure — that no acquirer can replicate organically.

We work directly with 76+ active U.S. lower middle market buyers, including 38 manufacturing-focused capital partners. On the medical device side specifically, the buyer pool includes three dedicated specialists — Linden Capital Partners (Chicago), Patient Square Capital, and LaSalle Capital — plus generalist healthcare and industrial PE platforms with active medical device mandates: Audax Group (Healthcare and Industrial vehicles), Madryn Asset Management, Genstar Capital, Arsenal Capital Partners, and Industrial Growth Partners (engineered products with medical device exposure). On the strategic side, public consolidators Stryker (NYSE: SYK), Becton Dickinson (NYSE: BDX), Boston Scientific (NYSE: BSX), Medtronic (NYSE: MDT), and Resmed (NYSE: RMD) acquire across the LMM medical device space. The buyers pay us when a deal closes — not you.

This guide is the canonical hub for selling a U.S. medical device manufacturing business in 2026. It covers buyer demand, multiples by size and product type, the five active buyer archetypes, named PE platforms with verifiable activity, the typical sale process, the drivers of premium multiples (ISO 13485, FDA, 510(k), MDSAP, recurring consumables), the deal-killers in diligence (Form 483 observations, recall history, customer concentration, MDR compliance), and how a buy-side partner is structurally different from a sell-side broker. If you want a starting-point valuation range now, our free valuation calculator takes about three minutes.

“Medical device is the only sub-vertical in U.S. industrial M&A where a $5M EBITDA business credibly trades for 11x. The reason is structural: ISO 13485 + FDA 21 CFR 820 + 510(k) clearance is a 5-10 year build-out moat that no buyer can replicate organically.”

Key Takeaways

• Medical device manufacturing commands 8-12x EBITDA standard; platform-quality assets with proprietary IP and recurring consumables push 12-15x.
• Multiples by EBITDA size: $1-3M = 7-9x; $3-7M = 8-10x; $7-15M = 9-12x; $15M+ = 10-14x for clean assets.
• Three dedicated medical device PE platforms: Linden Capital Partners (Chicago), Patient Square Capital, LaSalle Capital.
• Public strategic consolidators: Stryker (SYK), Becton Dickinson (BDX), Boston Scientific (BSX), Medtronic (MDT), Resmed (RMD).
• Premium drivers: ISO 13485 current, FDA registered with 510(k) clearances, no open Form 483, MDSAP / EU MDR compliance, proprietary IP, recurring consumables / disposables revenue.
• Top deal-killers: open FDA Form 483 observations, warning letters, recall history, MDR (medical device reporting) compliance gaps, customer concentration above 30%, EU MDR transition exposure.

Why medical device manufacturing commands the highest multiples in U.S. industrial M&A

Medical device is structurally different from generic manufacturing in four ways that drive multiple premium. First, the qualification moat: ISO 13485 + FDA 21 CFR 820 + 510(k) clearance + MDSAP / EU MDR compliance + validated cleanroom infrastructure represents a 5-10 year build-out that no acquirer can replicate organically. Second, the demand cycle: aging U.S. population (10,000 Americans turning 65 daily), expanding global access to healthcare, and ongoing technology innovation drive sustained backlog. Third, customer credit quality: hospital systems, GPOs (Vizient, Premier, HealthTrust), and large medtech OEMs (Stryker, BD, Boston Scientific, Medtronic) are investment-grade. Fourth, recurring revenue: many medical device categories include consumables / disposables that produce 30-60% recurring revenue with high gross margins.

On the supply side, medical device PE has matured into a dedicated category. Linden Capital Partners (Chicago, IL) is on its sixth fund and has built one of the most active medical device platform programs in U.S. PE. Patient Square Capital (founded 2020 by KKR alumni) raised a $3.9B inaugural fund focused on healthcare including medical devices. LaSalle Capital is a dedicated LMM healthcare PE firm with multiple medical device platform investments. Generalist healthcare PE (Audax Healthcare, Madryn, Genstar) and specialty industrial PE (Arsenal Capital, IGP) also bid in this space. Capital is dedicated, deep, and willing to pay the premium for qualification moat.

What this means for owner-operators of $1-25M EBITDA medical device manufacturing businesses. You are sitting in front of the most willing-to-pay-premium buyer pool in U.S. industrial M&A. The question is positioning — do you look like a platform-quality medical device asset (current ISO 13485 with no major findings, FDA registered with active 510(k) clearances, no open Form 483, recurring consumables revenue, diversified customers, second-tier QA / RA leadership) or do you look like a contract manufacturer with some medical exposure? The difference is 2-4 turns of EBITDA multiple, which on $5M EBITDA is $10-20M of purchase price.

Medical device manufacturing multiples in 2026: what the data shows

Medical device multiples are driven by EBITDA size, product type (own-IP vs contract manufacturing), recurring revenue mix, and regulatory standing. Size determines which buyer pool is active. Product type drives 1-3 turns of premium for own-IP businesses with 510(k) cleared products vs build-to-print contract manufacturers. Recurring revenue from consumables and disposables drives 1-2 turns of premium. Regulatory standing — ISO 13485, FDA registration, 510(k) clearances, MDSAP, EU MDR — is the qualification moat.

Generic medical device multiples by EBITDA size in 2026: $1-3M EBITDA: 7-9x — LMM PE add-on territory, light platform interest. $3-7M EBITDA: 8-10x — deep medical device PE platform territory, all three dedicated specialists active. $7-15M EBITDA: 9-12x — full medical device PE bidding, family offices, public strategics in pool. $15M+ EBITDA: 10-14x — mid-market PE process with strategic premiums available from Stryker, BD, Boston Scientific, Medtronic.

Product-type adjustments within medical device: Build-to-print contract manufacturer (no IP, customer-supplied designs): -1.5 to -2 turns vs band. CDMO with regulatory infrastructure (ISO 13485, FDA, validated processes): at par. CDMO with proprietary process IP (specialty injection molding, electrospinning, complex assembly): +0.5-1x. OEM with own 510(k) cleared products: +1-2 turns. OEM with proprietary IP and recurring consumables: +2-3 turns. PMA-cleared (vs 510(k)) Class III device manufacturer: +2-4 turns.

Recurring revenue and customer mix adjustments: Recurring consumables / disposables 30%+ of revenue: +1-2 turns. Top customer below 15% of revenue: at par to +0.5x. Top customer 15-25%: -0.5x. Top customer above 30%: -1 to -1.5x or earnout structure. Hospital / GPO direct relationships: +0.5x for stability. Large medtech OEM contract manufacturing customers (Stryker, Medtronic, BD): at par if multi-year contracts in place, -0.5x if at-will.

The 5 active buyer archetypes for medical device manufacturing

The buyer pool for U.S. medical device manufacturing divides into five archetypes. Medical device is similar to aerospace in having dedicated PE specialists who command outsized share of platform deals. Generalist healthcare PE bids competitively at the LMM end. Public strategics (Stryker, BD, Boston Scientific, Medtronic) bid at premium for the right strategic / IP fit.

Archetype 1: dedicated medical device PE platform. Three named specialists: Linden Capital Partners (Chicago, IL) — healthcare and medical products specialist with multiple medical device manufacturer platforms; sixth fund deployed. Patient Square Capital — healthcare-focused with significant medical device exposure; $3.9B inaugural fund. LaSalle Capital — dedicated LMM healthcare specialist. Multiples: 9-13x EBITDA at platform size. Process: deep regulatory diligence, FDA history review, full QoE. Best fit: $5M+ EBITDA medical device assets with current certifications and clean regulatory record.

Archetype 2: generalist healthcare / industrial PE with medical device mandate. Audax Group (Healthcare and Industrial vehicles) — deep healthcare and industrial portfolios with medical device crossover. Madryn Asset Management — healthcare-focused with medical device manufacturer exposure. Genstar Capital — healthcare and specialty industrial with medical device platform deals. Arsenal Capital Partners — specialty industrial including medical materials and device components. Industrial Growth Partners (IGP) — engineered industrial including medical device mechanical components. Multiples: 8-11x EBITDA. Best fit: $3-15M EBITDA medical device with strong industrial fundamentals.

Archetype 3: medical device PE add-on / tuck-in. Existing PE-backed medical device platforms acquiring smaller bolt-ons. Same named PE firms operating through portfolio companies. Multiples: 8-11x EBITDA, often with rollover equity. Faster close (60-120 days). Best fit: $1-7M EBITDA medical device businesses with capability or product fit to existing platform (e.g., specific assembly capability, niche cleanroom infrastructure, complementary 510(k) product family).

Archetype 4: public strategic / medtech consolidator. Stryker (NYSE: SYK) — surgical, orthopedic, neurotechnology; multiple acquisitions per year. Becton Dickinson (NYSE: BDX) — medical / surgical / diagnostics. Boston Scientific (NYSE: BSX) — cardiovascular and endoscopy. Medtronic (NYSE: MDT) — broad medtech. Resmed (NYSE: RMD) — respiratory care. Edwards Lifesciences (NYSE: EW), Hologic (NASDAQ: HOLX), Zimmer Biomet (NYSE: ZBH) — selective acquirers. Multiples: 11-16x EBITDA when strategic fit and IP align. Best fit: OEMs with proprietary 510(k) / PMA cleared products that complement strategic portfolio.

Archetype 5: family office with healthcare mandate. Family offices investing patient capital with longer hold horizons in healthcare manufacturing. Multiples: 7-10x EBITDA, often with rollover equity and continued seller involvement. Best fit: owners who care about legacy / employee retention and want partial liquidity but continued ownership in a regulated business they understand.

Buyer type	Cash at close	Rollover equity	Exclusivity	Best fit for
Strategic acquirer	High (40–60%+)	Low (0–10%)	60–90 days	Sellers who want a clean exit; competitor or upstream consolidator
PE platform	Medium (60–80%)	Medium (15–25%)	60–120 days	Sellers willing to hold rollover for the second sale; bigger deals
PE add-on	Higher (70–85%)	Low–Medium (10–20%)	45–90 days	Sellers folding into existing platform; faster process
Search fund / ETA	Medium (50–70%)	High (20–40%)	90–180 days	Legacy-conscious sellers wanting an owner-operator successor
Independent sponsor	Medium (55–75%)	Medium (15–30%)	60–120 days	Sellers OK with deal-by-deal capital and longer financing closes

Named PE platforms acquiring medical device manufacturing in 2026

Dedicated medical device PE platforms with verifiable 2025-2026 activity. Linden Capital Partners (Chicago) — healthcare and medical products specialist; portfolio includes multiple medical device manufacturer platforms across orthopedics, cardiovascular, surgical, and CDMO. Sixth fund deployed. Patient Square Capital — founded 2020 by former KKR healthcare leaders; $3.9B inaugural fund focused on healthcare including medical devices. LaSalle Capital — dedicated LMM healthcare specialist with medical device platform deals.

Generalist healthcare PE with active medical device 2025-2026 deals. Audax Group — medical device exposure across Healthcare and Industrial portfolios. Madryn Asset Management — healthcare-focused. Genstar Capital — healthcare and specialty industrial. Arsenal Capital Partners — specialty industrial with medical materials. Industrial Growth Partners (IGP) — engineered medical device mechanical components. GenNx360, Wynnchurch, Mason Wells — selective medical device platform investments.

Public strategic acquirers in medical device. Stryker (NYSE: SYK) — consistent multi-deal acquirer, surgical / orthopedic / neurotechnology focus. Becton Dickinson (NYSE: BDX) — broad medical / surgical / diagnostics. Boston Scientific (NYSE: BSX) — cardiovascular and endoscopy specialist. Medtronic (NYSE: MDT) — broad medtech with active acquisition program. Resmed (NYSE: RMD) — respiratory care. Edwards Lifesciences (NYSE: EW) — structural heart. Hologic (NASDAQ: HOLX) — women’s health diagnostics. Zimmer Biomet (NYSE: ZBH) — orthopedics.

Family offices and patient capital sources. Many of the 76+ buyers we work with are family offices that don’t publicize their healthcare activity but write checks for $5-25M EBITDA medical device platforms. They typically pay 1-2x below institutional medical device PE but offer longer hold periods, lighter operational change, and rollover equity options. For owner-operators who care about legacy and employee continuity, family-office buyers can deliver strong economics with better cultural fit.

The typical medical device M&A sale process

A medical device sell-side process for a $3M+ EBITDA business runs 9-12 months from prep-complete to close. Slightly longer than generic manufacturing because medical device diligence includes detailed FDA history review (Form 483 observations, warning letters, recalls, complaint records, MDR submissions), full QSR / ISO 13485 audit-readiness review, MDSAP / EU MDR compliance review, and 510(k) / PMA portfolio review. Add 12-24 months on the front for proper preparation if regulatory standing isn’t already current and clean.

Months 1-2: positioning, CIM build, buyer list. Build a 50-70 page CIM emphasizing regulatory standing (ISO 13485 status with audit history, FDA registration / 510(k) portfolio / MDSAP / EU MDR status, Form 483 history if any), product mix (own-IP vs contract manufacturing, 510(k) vs PMA), customer concentration profile, recurring consumables / disposables mix, and growth thesis. Build a target buyer list of 25-50 prospects: 3 dedicated medical device PE specialists, 8-12 generalist healthcare PE with medical device mandates, 5-10 PE add-on candidates, 3-6 public strategics, and 5-10 family offices.

Months 2-4: management meetings and IOIs. 8-12 buyers move into management presentations — typically a full-day on-site visit including operations / cleanroom walkthrough, QA / RA leadership review, FDA history deep-dive, customer / contract review, and Q&A. Receive 3-7 IOIs. Negotiate to 2-3 buyers for confirmatory diligence.

Months 4-8: LOI, exclusivity, confirmatory diligence. Sign LOI with 60-90 day exclusivity. QoE engagement ($100-200K). Medical device-specialized regulatory counsel reviews FDA history, MDR records, complaint files, recall history. Quality system audit by external consultant. Customer reference calls. Environmental Phase I for facility (cleanroom infrastructure typically lower environmental risk than chemical processing). Working capital target negotiation. Indemnification, R&W (with regulatory-specific reps), escrow, earnout terms negotiated.

Months 8-12: signing, regulatory clearance, close. Definitive purchase agreement signed. FDA establishment notification of ownership change (Form FDA 2891 amendment). Regulatory clearance (HSR if over threshold). Customer notifications per supply agreements. Final working capital adjustment. Employee notification. Closing — wire transfer, escrow funding, transition services agreement effective. Many medical device deals include a 6-18 month transition services agreement covering quality, regulatory, and customer relationship management.

Medical device-specific timeline disruptors. Open Form 483 observations or warning letters at sale require remediation before transfer. ISO 13485 surveillance audit findings during diligence can re-trade the deal. EU MDR transition exposure can compress multiples for products requiring re-certification. Customer-driven quality holds can derail LOI economics. Recall history (especially Class I or Class II) requires careful disclosure and impacts buyer underwriting.

What drives premium multiples in medical device manufacturing

Six characteristics drive 8x vs 13x outcomes in medical device M&A. Each is a structural driver of buyer underwriting. PE platforms model future cash flows against regulatory risk, customer credit quality, and qualification moat — each of these characteristics either de-risks the model or extends growth runway.

Driver 1: ISO 13485 current with no major findings. ISO 13485:2016 certification is the table-stakes quality system standard for medical device manufacturing. A clean recent surveillance audit with no major findings is a 1-2 turn driver. Lapsed certification or open major nonconformances can drop the deal entirely or compress to generic manufacturing multiples.

Driver 2: FDA registered with 510(k) clearances and no open 483. FDA establishment registration current. 510(k) (or PMA for Class III) clearances active. No open Form 483 observations from recent FDA inspections. No warning letters in the last 5 years. No recall history (or only fully-closed Class III recalls). This regulatory standing represents 1-3 turns of premium — and the absence of it is often a deal-killer.

Driver 3: proprietary IP and own-product mix. Build-to-print CDMOs trade at 7-8x. CDMOs with proprietary process IP (validated processes that are difficult to replicate) trade at 8-9x. OEMs with proprietary 510(k) / PMA cleared products trade at 10-13x. Patent estate, trade secrets, validated process know-how, and product portfolio all factor in. Document IP rigorously in CIM.

Driver 4: recurring consumables / disposables revenue. Capital equipment (instruments, devices) drives initial revenue, but consumables / disposables drive recurring revenue at high gross margins (often 60-80%). Businesses with 30%+ recurring consumables revenue trade at 1-2 turns premium. Razor-and-blades model is the medtech ideal.

Driver 5: customer diversification. Top customer below 15% of revenue: premium territory. Top customer 15-25%: at par. Top customer 25-30%: -0.5x. Above 30%: -1 to -1.5x or earnout structure. Concentration with large medtech OEMs (Stryker, BD, Medtronic, Boston Scientific) is somewhat better tolerated than with mid-tier customers because the credit quality is investment-grade.

Driver 6: international compliance (MDSAP, EU MDR). MDSAP (Medical Device Single Audit Program) covers U.S., Canada, Brazil, Australia, Japan with single audit. EU MDR (Medical Device Regulation) is the EU’s post-2021 framework. Businesses with current MDSAP and EU MDR compliance have international growth runway and trade at 0.5-1x premium. Businesses without face EU revenue exposure during the buyer’s hold period.

Common deal-killers in medical device M&A diligence

Five issues kill or re-trade more medical device LOIs than any others. Medical device adds three regulatory deal-killers (Form 483, warning letters, recalls) on top of the generic manufacturing list. Each is preventable with 12-24 months of pre-process preparation. Each is also discovered late in diligence by 90% of unprepared sellers.

Deal-killer 1: open Form 483 observations or warning letters. FDA Form 483 observations from inspections, especially if not yet closed, signal quality system risk. Warning letters in the last 5 years are a major red flag. Each can drop the deal or trigger 1-2x multiple compression. Fix: close all Form 483 observations within FDA-acceptable timeframes; resolve warning letters before market; document remediation rigorously.

Deal-killer 2: recall history, especially Class I. Recall history is reviewed in detail by buyer’s regulatory counsel. Class I recalls (serious adverse events possible) are particularly damaging. Class II recalls are manageable if properly closed. Class III (minor labeling issues) are typically not deal-impacting. Fix: ensure all recalls are closed with documented effectiveness; address any open recall liabilities in escrow / indemnification.

Deal-killer 3: customer concentration above 30%. Even with investment-grade medtech OEM customers, concentration above 30% compresses multiples 1-1.5x or pushes the deal into earnout structures tied to customer retention. Fix: 12-18 months of intentional customer diversification, additional OEM customer development, formal multi-year supply agreements with assignment provisions.

Deal-killer 4: EU MDR transition exposure. EU Medical Device Regulation (MDR) requires re-certification of products previously CE-marked under the Medical Device Directive. Products without MDR-compliant CE marks at market entry can face EU revenue loss. Buyers underwrite this aggressively. Fix: complete MDR transition for material EU products before going to market, or document the compliance roadmap with budget.

Deal-killer 5: aggressive add-backs that don’t survive QoE. Owner’s personal expenses, family-member compensation without substance, one-time R&D project costs claimed as ongoing. QoE providers will systematically challenge each. On a 10x multiple, $300K of rejected add-backs cuts $3M off the purchase price. Fix: have your accountant quantify add-backs conservatively and document each line.

How CT Acquisitions works: a buy-side partner, not a sell-side broker

Most M&A advisors are sell-side brokers. They sign you to a 12-month exclusive engagement, charge a monthly retainer ($10-25K is common in LMM), run a competitive auction process across 6-12 months, and collect a success fee (typically 5-10% of deal value, often $500K-$2M+ on a $10-25M medical device deal). The economics are heavily front-loaded for the broker.

We work the other side of the table. We’re a buy-side partner working with 76+ active U.S. lower middle market buyers, including 38 manufacturing-focused capital partners. On the medical device side specifically, we have direct working relationships with the three dedicated specialists (Linden Capital, Patient Square, LaSalle Capital) plus generalist healthcare and industrial PE platforms with active medical device mandates. The buyers pay us when a deal closes, not you. No retainer. No exclusivity. No 12-month contract. No tail fee.

Why this works for medical device owners. We already know which of the 76+ buyers is currently writing checks for your sub-segment (orthopedic vs cardiovascular vs surgical vs CDMO vs respiratory) and size. We can introduce you to 3-5 buyers with active mandates that fit your business in days, not months. We move faster (60-120 days from intro to LOI) because we’re not running an auction to find buyers — we already know them. And the cost-of-trying is zero, so the conversation is downside-protected.

When a sell-side broker is the better fit. If your business is $40M+ EBITDA medical device with multiple plausible strategic buyers (Stryker, BD, Medtronic, Boston Scientific) all credibly in the bidding pool, a top-tier sell-side investment bank with medical device expertise may justify the fees. For LMM medical device ($1-30M EBITDA), the buy-side path almost always delivers better economics.

Conclusion

Medical device manufacturing trades at the highest multiples in U.S. industrial M&A in 2026. 8-12x EBITDA standard, 12-15x for proprietary IP and recurring consumables platform-quality assets. Three dedicated PE specialists (Linden Capital, Patient Square, LaSalle Capital) plus generalist healthcare and industrial PE platforms (Audax, Madryn, Genstar, Arsenal Capital, IGP). Public consolidators (Stryker SYK, Becton Dickinson BDX, Boston Scientific BSX, Medtronic MDT, Resmed RMD) at premium multiples for the right strategic / IP fit. The premium drivers are clear: ISO 13485 current, FDA registered with active 510(k) clearances and no open Form 483, proprietary IP with own-product mix, recurring consumables / disposables 30%+, diversified customers, MDSAP and EU MDR compliance. The deal-killers are equally clear: open Form 483 observations or warning letters, Class I or II recall history, customer concentration above 30%, EU MDR transition exposure, aggressive add-backs that don’t survive QoE. Owners who prepare 12-24 months ahead and position to the right buyer archetype see 2-4 turns of multiple uplift — on $5M EBITDA, that’s $10-20M of additional purchase price. If you want to talk to a buy-side partner who already knows the 76+ buyers and the medical device specialists specifically, we’re a buy-side partner — the buyers pay us, not you, no contract required.

Frequently Asked Questions

What is my medical device manufacturing business worth in 2026?

Generic ranges by EBITDA: $1-3M = 7-9x; $3-7M = 8-10x; $7-15M = 9-12x; $15M+ = 10-14x. Product-type adjustments: build-to-print CDMO -1.5 to -2x, OEM with own 510(k) +1-2x, OEM with proprietary IP and recurring consumables +2-3x, PMA-cleared Class III +2-4x. Recurring consumables 30%+ adds 1-2x within band.

Who buys medical device manufacturing businesses?

Three dedicated medical device PE specialists: Linden Capital Partners (Chicago), Patient Square Capital, LaSalle Capital. Generalist healthcare / industrial PE: Audax, Madryn, Genstar, Arsenal Capital, IGP. Public strategics: Stryker (NYSE: SYK), Becton Dickinson (NYSE: BDX), Boston Scientific (NYSE: BSX), Medtronic (NYSE: MDT), Resmed (NYSE: RMD), Edwards Lifesciences, Hologic, Zimmer Biomet.

How important are ISO 13485 and FDA 510(k) for premium multiples?

ISO 13485:2016 current with no major findings is table-stakes — a 1-2 turn driver and required for most buyers. FDA registration with active 510(k) clearances (or PMA for Class III) and no open Form 483 observations adds another 1-3 turns. Lapsed certifications, open warning letters, or recall history can drop the deal entirely or compress to generic manufacturing multiples (5-7x vs 8-12x).

What about Form 483 observations and warning letters?

Open Form 483 observations from FDA inspections, especially recent ones, are major red flags. Warning letters in the last 5 years are deal-impacting. Buyers’ regulatory counsel review FDA history rigorously. Pre-process: close all 483 observations within FDA-acceptable timeframes, resolve warning letters before market, document remediation rigorously. Recall history (Class I most damaging) requires careful disclosure.

How does customer concentration affect my multiple?

Top customer below 15%: premium. 15-25%: at par. 25-30%: -0.5x. Above 30%: -1 to -1.5x or earnout structure. Concentration with investment-grade medtech OEMs (Stryker, BD, Medtronic, Boston Scientific) is somewhat better tolerated, but still discounts. Fix over 12-18 months: aggressive new-customer development, multi-year supply agreements, additional OEM qualifications.

How long does a medical device sale process take?

9-12 months from prep-complete to close for a $3M+ EBITDA medical device business. Slightly longer than generic manufacturing because of FDA history review, ISO 13485 audit-readiness review, MDSAP / EU MDR compliance review, and 510(k) / PMA portfolio review. Add 12-24 months for proper preparation if regulatory standing isn’t already current and clean.

How is CT Acquisitions different from a sell-side broker or M&A advisor?

We’re a buy-side partner, not a sell-side broker. Sell-side brokers represent you and charge you 8-12% of the deal (often $500K-$2M+ on medical device) plus monthly retainers and require 12-month exclusivity. We work directly with 76+ buyers including 38 manufacturing-focused capital partners and the three dedicated medical device specialists (Linden Capital, Patient Square, LaSalle Capital). The buyers pay us when a deal closes. You pay nothing. No retainer, no exclusivity, no contract. We move faster (60-120 days from intro to LOI) because we already know who the right buyer is.

Sources & References

All claims and figures in this analysis are sourced from the publicly available references below.

1. U.S. FDA — Medical Device Quality System Regulation 21 CFR 820
2. U.S. FDA — 510(k) Premarket Notification
3. ISO 13485:2016 — Medical Devices Quality Management Systems
4. Linden Capital Partners — Healthcare Investment Strategy
5. Patient Square Capital — Healthcare Investment Strategy
6. Stryker Corporation (NYSE: SYK) — Investor Relations and Acquisition Activity
7. Becton Dickinson (NYSE: BDX) — Investor Relations
8. AdvaMed — Medical Device Industry Resources